ATR
APTARGROUP, INC.
Next earnings Jul 30, 2026 · consensus $1.37 EPS, $1.02B rev
Last earnings +0.6% on 2026-04-30
$126.98
▲ +1.35%$126.98▼ -17.34%
over 1Y
L $111.94H $159.97
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.3%
1W+0.4%
1M+13.2%
3M+1.2%
YTD+4.4%
1Y-17.3%
Buy
Conviction
Horizon
Long (>12mo)
Street · 12 analysts
Buy
Steady pharma-leaning dispensing-systems compounder with consistent growth and 15% ROE at a fair 20x.
Revenue (FY2025) $3.78B · FY2025
The read
The fundamentals carry the rating, but the price is rich (~25% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.
AptarGroup makes dispensing, sealing and drug-delivery systems for the pharma, beauty and consumer markets, with the high-value pharma segment (nasal sprays, injectables, inhalation devices) anchoring its quality. The track record is one of dependable compounding: revenue rose 5.4% to $3.78B in FY2025 and has climbed every year from $3.23B in FY2021, while net income grew 4.9% to $393M (up from $244M in FY2021) and diluted EPS rose 6.5% to $5.89. Margins are solid and stable for a packaging company — 24.0% gross, 13.3% operating, 10.4% net — and return on equity is a healthy 14.7%.
The balance sheet and cash generation support the franchise. Equity grew 7.9% to $2.67B, retained earnings rose 11.5%, cash jumped 79.8% to $402M, and debt is modest. Capital allocation is shareholder-friendly: the company stepped up buybacks dramatically to $365M (up 431.8%, reducing shares 3.2%) and raised the dividend 5.9% to $121M. The one soft spot is operating cash flow, which fell 11.4% to $570M on working-capital/capex timing ($270M capex), worth monitoring but not alarming given the rising cash balance.
Is ATR a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBull call spread~90d expiry
- Long call 127 @ ~6.04 est
- Short call 140 @ ~1.64 est
debit $440max +$860max −$440BE 131.40
BUY verdict with defined risk: the short call finances part of the long one; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $3.23B | $3.32B | $3.49B | $3.58B | $3.78B |
| Gross profit | — | — | — | — | — |
| Operating income | $347M | $379M | $404M | $496M | $501M |
| Net income | $244M | $239M | $284M | $375M | $393M |
| Diluted EPS | $3.61 | $3.59 | $4.25 | $5.53 | $5.89 |
| Net margin | 7.6% | 7.2% | 8.2% | 10.5% | 10.4% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$7.89B
EV / EBITDA10.0
EV / Sales2.1
EV / FCF26.3
P / FCF27.1
PEG (trailing)4.42
Earnings yield4.8%
FCF yield3.7%
Quality & risk
ROIC (est.)13.9%
Free cash flow$300M
Total debt$184M
Net cash$218M
Piotroski F-Score5/8
Capital returns
Buyback yield4.5%
Dividend yield (est.)1.5%
Shareholder yield6.0%
Shares Δ YoY-3.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-152026-06-16open ↗11-KPeriod ending 2025-12-312026-06-10open ↗4Period ending 2026-06-092026-06-10open ↗144Filing2026-06-09open ↗3Period ending 2026-06-082026-06-08open ↗4Period ending 2026-06-042026-06-05open ↗144Filing2026-06-04open ↗4Period ending 2026-05-262026-05-27open ↗144Filing2026-05-26open ↗4Period ending 2026-05-212026-05-21open ↗SDFiling2026-05-18open ↗8-KPeriod ending 2026-05-102026-05-13open ↗
Frequently asked
- Is APTARGROUP, INC. (ATR) a buy?
- ATR currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. Steady pharma-leaning dispensing-systems compounder with consistent growth and 15% ROE at a fair 20x.
- What is ATR's fair value?
- A Modified-Graham model based on ATR's SEC fundamentals estimates a fair value of about $95.54. It is an estimate from reported earnings, not a price target.
- Is ATR overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, ATR currently appears overvalued relative to its SEC-grounded earnings power.
- What is APTARGROUP, INC.'s quality score?
- ATR scores 66.79027562737771/100 (grade B-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000896622, latest 10-Q filed 2026-05-01) · EODHD · Proprietary analysis · as of 6/21/2026, 8:53:31 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:53 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.